Reference
1. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. The Lancet infectious diseases. 2016;16(8):935-41.
2. Malavige GN, Wijewickrama A, Fernando S, Jeewandara C, Ginneliya A, Samarasekara S, et al. A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection. Sci Rep. 2018;8(1):3857.
3. Ang LW, Thein TL, Ng Y, Boudville IC, Chia PY, Lee VJM, et al. A 15-year review of dengue hospitalizations in Singapore: Reducing admissions without adverse consequences, 2003 to 2017. PLoS neglected tropical diseases. 2019;13(5):e0007389.
4. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS neglected tropical diseases. 2010;4(8):e785.
5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-7.
6. Murhekar MV, Kamaraj P, Kumar MS, Khan SA, Allam RR, Barde P, et al. Burden of dengue infection in India, 2017: a cross-sectional population based serosurvey. Lancet Glob Health. 2019;7(8):e1065-e73.
7. Malavige GN, Ogg GS. Pathogenesis of vascular leak in dengue virus infection. Immunology. 2017;151(3):261-9.
8. Gomes L, Fernando S, Fernando RH, Wickramasinghe N, Shyamali NL, Ogg GS, et al. Sphingosine 1-phosphate in acute dengue infection. PloS one. 2014;9(11):e113394.
9. Jeewandara C, Gomes L, Wickramasinghe N, Gutowska-Owsiak D, Waithe D, Paranavitane SA, et al. Platelet activating factor contributes to vascular leak in acute dengue infection. PLoS neglected tropical diseases. 2015;9(2):e0003459.
10. Puerta-Guardo H, Glasner DR, Harris E. Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability. PLoS pathogens. 2016;12(7):e1005738.
11. Hottz ED, Lopes JF, Freitas C, Valls-de-Souza R, Oliveira MF, Bozza MT, et al. Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. Blood. 2013;122(20):3405-14.
12. St John AL, Rathore AP, Raghavan B, Ng ML, Abraham SN. Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage. Elife. 2013;2:e00481.
13. Jeewandara C, Gomes L, Udari S, Paranavitane SA, Shyamali NL, Ogg GS, et al. Secretory phospholipase A2 in the pathogenesis of acute dengue infection. Immun Inflamm Dis. 2017;5(1):7-15.
14. Bennett M, Gilroy DW. Lipid Mediators in Inflammation. Microbiol Spectr. 2016;4(6).
15. Ogawa Y, Calhoun WJ. The role of leukotrienes in airway inflammation. The Journal of allergy and clinical immunology. 2006;118(4):789-98; quiz 99-800.
16. Joris I, Majno G, Corey EJ, Lewis RA. The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. The American journal of pathology. 1987;126(1):19-24.
17. Loke WM, Chow AY, Lam Mok Sing K, Lee CY, Halliwell B, Lim EC, et al. Augmentation of 5-lipoxygenase activity and expression during dengue serotype-2 infection. Virology journal. 2013;10:322.
18. WHO, editor. Comprehensive guidelines for prevention and control of dengue fever and dengue haemorrhagic fever. SEARO, New Delhi, India: World Health Organization; 2011.
19. Fernando S, Wijewickrama A, Gomes L, Punchihewa CT, Madusanka SD, Dissanayake H, et al. Patterns and causes of liver involvement in acute dengue infection. BMC infectious diseases. 2016;16:319.
20. Tissera H, Rathore APS, Leong WY, Pike BL, Warkentien TE, Farouk FS, et al. Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients. The Journal of infectious diseases. 2017;216(9):1112-21.
21. Cui L, Lee YH, Thein TL, Fang J, Pang J, Ooi EE, et al. Serum Metabolomics Reveals Serotonin as a Predictor of Severe Dengue in the Early Phase of Dengue Fever. PLoS neglected tropical diseases. 2016;10(4):e0004607.
22. Furuta T, Murao LA, Lan NT, Huy NT, Huong VT, Thuy TT, et al. Association of mast cell-derived VEGF and proteases in Dengue shock syndrome. PLoS neglected tropical diseases. 2012;6(2):e1505.
23. Rathore AP, Mantri CK, Aman SA, Syenina A, Ooi J, Jagaraj CJ, et al. Dengue virus-elicited tryptase induces endothelial permeability and shock. The Journal of clinical investigation. 2019;130:4180-93.
24. Chiu CY, Tsai MH, Yao TC, Tu YL, Hua MC, Yeh KW, et al. Urinary LTE4 levels as a diagnostic marker for IgE-mediated asthma in preschool children: a birth cohort study. PloS one. 2014;9(12):e115216.
25. Syenina A, Jagaraj CJ, Aman SA, Sridharan A, St John AL. Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fcgamma receptors. Elife. 2015;4.
26. Asano K, Lilly CM, O’Donnell WJ, Israel E, Fischer A, Ransil BJ, et al. Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. The Journal of allergy and clinical immunology. 1995;96(5 Pt 1):643-51.
27. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev. 2007;27(4):469-527.
28. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, et al. IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity. Science. 2017;355(6323):395-8.
29. Reicin A, White R, Weinstein SF, Finn AF, Jr., Nguyen H, Peszek I, et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Archives of internal medicine. 2000;160(16):2481-8.
30. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2006;97(5):664-71.
31. Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, et al. The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets. Frontiers in immunology. 2018;9:1873.
32. Huang H, Li Y, Liang J, Finkelman FD. Molecular Regulation of Histamine Synthesis. Frontiers in immunology. 2018;9:1392.
33. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). The Journal of pharmacology and experimental therapeutics. 1997;280(1):114-21.